Medicare Program; Application From Community Health Accreditation Partner (CHAP) for Initial CMS-Approval of Its Home Infusion Therapy Accreditation Program, 23364-23365 [2020-08796]
Download as PDF
23364
Federal Register / Vol. 85, No. 81 / Monday, April 27, 2020 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–08793 Filed 4–24–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3393–PN]
Medicare Program; Application From
Community Health Accreditation
Partner (CHAP) for Initial CMSApproval of Its Home Infusion Therapy
Accreditation Program
Centers for Medicare and
Medicaid Services, HHS.
ACTION: Notice with request for
comment.
AGENCY:
This proposed notice
acknowledges the receipt of an
application from Community Health
Accreditation Partner for initial
recognition as a national accrediting
organization for suppliers of home
infusion therapy services that wish to
participate in the Medicare program.
The statute requires that within 60 days
of receipt of an organization’s complete
application, the Centers for Medicare &
Medicaid Services (CMS) publish a
notice that identifies the national
accrediting body making the request,
describes the nature of the request, and
provides at least a 30-day public
comment period.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, no later
than 5 p.m. on May 27, 2020.
ADDRESSES: In commenting, please refer
to file code CMS–3393–PN.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3393–PN, P.O. Box 8016,
Baltimore, MD 21244–8010.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
lotter on DSKBCFDHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:32 Apr 24, 2020
Jkt 250001
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3393–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Christina Mister-Ward, (410)786–2441.
Shannon Freeland, (410) 786- 4348.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following
website as soon as possible after they
have been received: https://
www.regulations.gov. Follow the search
instructions on that website to view
public comments.
I. Background
Home infusion therapy (HIT) is a
treatment option for Medicare
beneficiaries with a wide range of acute
and chronic conditions. Section 5012 of
the 21st Century Cures Act (Pub. L. 114–
255, enacted December 13, 2016) added
section 1861(iii) to the Social Security
Act (the Act), establishing a new
Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines
‘‘home infusion therapy’’ as professional
services, including nursing services;
training and education not otherwise
covered under the Durable Medical
Equipment (DME) benefit; remote
monitoring; and other monitoring
services. Home infusion therapy must
be furnished by a qualified HIT supplier
and furnished in the individual’s home.
The individual must:
• Be under the care of an applicable
provider (that is, physician, nurse
practitioner, or physician assistant); and
• Have a plan of care established and
periodically reviewed by a physician in
coordination with the furnishing of
home infusion drugs under Part B, that
prescribes the type, amount, and
duration of infusion therapy services
that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act
requires that a qualified HIT supplier be
accredited by an accrediting
organization (AO) designated by the
Secretary in accordance with section
1834(u)(5) of the Act. Section
1834(u)(5)(A) of the Act identifies
factors for designating AOs and in
reviewing and modifying the list of
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
designated AOs. These statutory factors
are as follows:
• The ability of the organization to
conduct timely reviews of accreditation
applications.
• The ability of the organization to
take into account the capacities of
suppliers located in a rural area (as
defined in section 1886(d)(2)(D) of the
Act).
• Whether the organization has
established reasonable fees to be
charged to suppliers applying for
accreditation.
• Such other factors as the Secretary
determines appropriate.
Section 1834(u)(5)(B) of the Act
requires the Secretary to designate AOs
to accredit HIT suppliers furnishing HIT
not later than January 1, 2021. Section
1861(iii)(3)(D)(i)(III) of the Act requires
a ‘‘qualified home infusion therapy
supplier’’ to be accredited by a CMSapproved AO, pursuant to section
1834(u)(5) of the Act.
On March 1, 2019, we published a
solicitation notice entitled, ‘‘Medicare
Program; Solicitation of Independent
Accrediting Organizations To
Participate in the Home Infusion
Therapy Supplier Accreditation
Program’’ (84 FR 7057). This notice
informed national AOs that accredit HIT
suppliers of an opportunity to submit
applications to participate in the HIT
supplier accreditation program. We
stated that complete applications would
be considered for the January 1, 2021
designation deadline if received by
February 1, 2020.
Regulations for the approval and
oversight of AOs for HIT organizations
are located at 42 CFR part 488, subpart
L. The requirements for HIT suppliers
are located at 42 CFR part 486, subpart
I.
II. Approval of Accreditation
Organizations
Section 1834(u)(5) of the Act and the
regulations at § 488.1010 require that
our findings concerning review and
approval of a national AO’s
requirements consider, among other
factors, the applying AO’s requirements
for accreditation; survey procedures;
resources for conducting required
surveys; capacity to furnish information
for use in enforcement activities;
monitoring procedures for provider
entities found not in compliance with
the conditions or requirements; and
ability to provide CMS with the
necessary data.
Section 488.1020(a) requires that we
publish, after receipt of an
organization’s complete application, a
notice identifying the national
accrediting body making the request,
E:\FR\FM\27APN1.SGM
27APN1
Federal Register / Vol. 85, No. 81 / Monday, April 27, 2020 / Notices
describing the nature of the request, and
providing at least a 30-day public
comment period. In accordance with
§ 488.1010(d), we have 210 days from
the receipt of a complete application to
publish notice of approval or denial of
the application.
The purpose of this proposed notice
is to inform the public of Community
Health Accreditation Partner (CHAP)
initial request for CMS’s approval of its
HIT accreditation program. This notice
also solicits public comment on whether
CHAP’s requirements meet or exceed
the Medicare conditions of participation
for HIT services.
lotter on DSKBCFDHB2PROD with NOTICES
III. Evaluation of Deeming Authority
Request
CHAP submitted all the necessary
materials to enable us to make a
determination concerning its request for
initial approval of its HIT accreditation
program. This application was
determined to be complete on February
27, 2020. Under section 1834(u)(5) of
the Act and § 488.1010 (Application and
re-application procedures for national
HIT AOs), our review and evaluation of
CHAP will be conducted in accordance
with, but not necessarily limited to, the
following factors:
• The equivalency of CHAP’s
standards for HIT as compared with
CMS’ HIT conditions for certification.
• CHAP’s survey process to
determine the following:
++ The composition of the survey
team, surveyor qualifications, and the
ability of the organization to provide
continuing surveyor training.
++ The comparability of CHAP’s to
CMS standards and processes, including
survey frequency, and the ability to
investigate and respond appropriately to
complaints against accredited facilities.
++ CHAP’s processes and procedures
for monitoring a HIT supplier found out
of compliance with CHAP’s program
requirements.
++ CHAP’s capacity to report
deficiencies to the surveyed supplier
and respond to the suppliers’ plan of
correction in a timely manner.
++ CHAP’s capacity to provide CMS
with electronic data and reports
necessary for effective assessment and
interpretation of the organization’s
survey process.
++ The adequacy of CHAP’s staff and
other resources, and its financial
viability.
++ CHAP’s capacity to adequately
fund required surveys.
++ CHAP’s policies with respect to
whether surveys are announced or
unannounced, to assure that surveys are
unannounced.
VerDate Sep<11>2014
17:32 Apr 24, 2020
Jkt 250001
++ CHAP’s agreement to provide CMS
with a copy of the most current
accreditation survey together with any
other information related to the survey
as CMS may require (including
corrective action plans).
• CHAP’s agreement or policies for
voluntary and involuntary termination
of suppliers.
• CHAP agreement or policies for
voluntary and involuntary termination
of the HIT AO program.
• CHAP’s policies and procedures to
avoid conflicts of interest, including the
appearance of conflicts of interest,
involving individuals who conduct
surveys or participate in accreditation
decisions.
IV. Collection of Information
Requirements
This document does not impose
information collection and
requirements; that is, reporting,
recordkeeping or third party disclosure
requirements. Consequently, there is no
need for review by the Office of
Management and Budget under the
authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq).
V. Response to Public Comments
Because of the large number of public
comments we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
comments we receive by the date and
time specified in the DATES section of
this preamble, and, when we proceed
with a subsequent document, we will
respond to the comments in the
preamble to that document.
Upon completion of our evaluation,
including evaluation of comments
received as a result of this notice, we
will publish a final notice in the Federal
Register announcing the result of our
evaluation.
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Seema Verma, having reviewed and
approved this document, authorizes
Evell J. Barco Holland, who is the
Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Dated: April 14, 2020.
Evell J. Barco Holland,
Federal Register Liaison, Department of
Health and Human Services.
[FR Doc. 2020–08796 Filed 4–24–20; 8:45 am]
BILLING CODE 4120–01–P
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
23365
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–N–0892]
Prospective Grant of an Exclusive
Patent License: Development,
Production, and Commercialization of
a Seasonal Influenza Vaccine
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The U.S. Food and Drug
Administration (FDA) is contemplating
the grant of an Exclusive Patent License
to practice the inventions embodied in
the Patents and Patent Applications
listed in the SUPPLEMENTARY
INFORMATION section of this notice to
Sciogen Inc. located in San Jose,
California.
SUMMARY:
Only written comments and/or
complete applications for a license
which are received by the FDA
Technology Transfer Program within 15
days from the date of publication of this
notice in the Federal Register will be
considered.
DATES:
Requests for copies of the
patent applications, inquiries, including
inquiries concerning license
applications, and comments and
objections relating to the contemplated
Exclusive Patent License should be
directed to William Ronnenberg, Lead
Patent Advisor, Technology Transfer
Program, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993;
FDAInventionLicensing@fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
William Ronnenberg, Lead Patent
Advisor, Technology Transfer Program,
Food and Drug Administration, 10903
New Hampshire Ave., Silver Spring, MD
20993; 240–402–4561,
FDAInventionLicensing@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
1. U.S. Patent No. 9,163,068 issued
October 20, 2015, entitled, ‘‘Influenza
Virus Recombinant Proteins’’ (FDA Ref.
No. E–2010–004/US–03).
2. U.S. Patent No. 9,896,484 issued
February 20, 2018, entitled, ‘‘Influenza
Virus Recombinant Proteins’’ (FDA Ref.
No. E–2010–004/US–04).
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States.
The prospective exclusive license
territory may be limited to the United
States for certain of the rights, or
E:\FR\FM\27APN1.SGM
27APN1
Agencies
[Federal Register Volume 85, Number 81 (Monday, April 27, 2020)]
[Notices]
[Pages 23364-23365]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08796]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3393-PN]
Medicare Program; Application From Community Health Accreditation
Partner (CHAP) for Initial CMS-Approval of Its Home Infusion Therapy
Accreditation Program
AGENCY: Centers for Medicare and Medicaid Services, HHS.
ACTION: Notice with request for comment.
-----------------------------------------------------------------------
SUMMARY: This proposed notice acknowledges the receipt of an
application from Community Health Accreditation Partner for initial
recognition as a national accrediting organization for suppliers of
home infusion therapy services that wish to participate in the Medicare
program. The statute requires that within 60 days of receipt of an
organization's complete application, the Centers for Medicare &
Medicaid Services (CMS) publish a notice that identifies the national
accrediting body making the request, describes the nature of the
request, and provides at least a 30-day public comment period.
DATES: To be assured consideration, comments must be received at one of
the addresses provided below, no later than 5 p.m. on May 27, 2020.
ADDRESSES: In commenting, please refer to file code CMS-3393-PN.
Comments, including mass comment submissions, must be submitted in
one of the following three ways (please choose only one of the ways
listed):
1. Electronically. You may submit electronic comments on this
regulation to https://www.regulations.gov. Follow the ``Submit a
comment'' instructions.
2. By regular mail. You may mail written comments to the following
address ONLY: Centers for Medicare & Medicaid Services, Department of
Health and Human Services, Attention: CMS-3393-PN, P.O. Box 8016,
Baltimore, MD 21244-8010.
Please allow sufficient time for mailed comments to be received
before the close of the comment period.
3. By express or overnight mail. You may send written comments to
the following address ONLY: Centers for Medicare & Medicaid Services,
Department of Health and Human Services, Attention: CMS-3393-PN, Mail
Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.
For information on viewing public comments, see the beginning of
the SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Christina Mister-Ward, (410)786-2441.
Shannon Freeland, (410) 786- 4348.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All comments received before the
close of the comment period are available for viewing by the public,
including any personally identifiable or confidential business
information that is included in a comment. We post all comments
received before the close of the comment period on the following
website as soon as possible after they have been received: https://www.regulations.gov. Follow the search instructions on that website to
view public comments.
I. Background
Home infusion therapy (HIT) is a treatment option for Medicare
beneficiaries with a wide range of acute and chronic conditions.
Section 5012 of the 21st Century Cures Act (Pub. L. 114-255, enacted
December 13, 2016) added section 1861(iii) to the Social Security Act
(the Act), establishing a new Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines ``home infusion therapy'' as
professional services, including nursing services; training and
education not otherwise covered under the Durable Medical Equipment
(DME) benefit; remote monitoring; and other monitoring services. Home
infusion therapy must be furnished by a qualified HIT supplier and
furnished in the individual's home. The individual must:
Be under the care of an applicable provider (that is,
physician, nurse practitioner, or physician assistant); and
Have a plan of care established and periodically reviewed
by a physician in coordination with the furnishing of home infusion
drugs under Part B, that prescribes the type, amount, and duration of
infusion therapy services that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act requires that a
qualified HIT supplier be accredited by an accrediting organization
(AO) designated by the Secretary in accordance with section 1834(u)(5)
of the Act. Section 1834(u)(5)(A) of the Act identifies factors for
designating AOs and in reviewing and modifying the list of designated
AOs. These statutory factors are as follows:
The ability of the organization to conduct timely reviews
of accreditation applications.
The ability of the organization to take into account the
capacities of suppliers located in a rural area (as defined in section
1886(d)(2)(D) of the Act).
Whether the organization has established reasonable fees
to be charged to suppliers applying for accreditation.
Such other factors as the Secretary determines
appropriate.
Section 1834(u)(5)(B) of the Act requires the Secretary to
designate AOs to accredit HIT suppliers furnishing HIT not later than
January 1, 2021. Section 1861(iii)(3)(D)(i)(III) of the Act requires a
``qualified home infusion therapy supplier'' to be accredited by a CMS-
approved AO, pursuant to section 1834(u)(5) of the Act.
On March 1, 2019, we published a solicitation notice entitled,
``Medicare Program; Solicitation of Independent Accrediting
Organizations To Participate in the Home Infusion Therapy Supplier
Accreditation Program'' (84 FR 7057). This notice informed national AOs
that accredit HIT suppliers of an opportunity to submit applications to
participate in the HIT supplier accreditation program. We stated that
complete applications would be considered for the January 1, 2021
designation deadline if received by February 1, 2020.
Regulations for the approval and oversight of AOs for HIT
organizations are located at 42 CFR part 488, subpart L. The
requirements for HIT suppliers are located at 42 CFR part 486, subpart
I.
II. Approval of Accreditation Organizations
Section 1834(u)(5) of the Act and the regulations at Sec. 488.1010
require that our findings concerning review and approval of a national
AO's requirements consider, among other factors, the applying AO's
requirements for accreditation; survey procedures; resources for
conducting required surveys; capacity to furnish information for use in
enforcement activities; monitoring procedures for provider entities
found not in compliance with the conditions or requirements; and
ability to provide CMS with the necessary data.
Section 488.1020(a) requires that we publish, after receipt of an
organization's complete application, a notice identifying the national
accrediting body making the request,
[[Page 23365]]
describing the nature of the request, and providing at least a 30-day
public comment period. In accordance with Sec. 488.1010(d), we have
210 days from the receipt of a complete application to publish notice
of approval or denial of the application.
The purpose of this proposed notice is to inform the public of
Community Health Accreditation Partner (CHAP) initial request for CMS's
approval of its HIT accreditation program. This notice also solicits
public comment on whether CHAP's requirements meet or exceed the
Medicare conditions of participation for HIT services.
III. Evaluation of Deeming Authority Request
CHAP submitted all the necessary materials to enable us to make a
determination concerning its request for initial approval of its HIT
accreditation program. This application was determined to be complete
on February 27, 2020. Under section 1834(u)(5) of the Act and Sec.
488.1010 (Application and re-application procedures for national HIT
AOs), our review and evaluation of CHAP will be conducted in accordance
with, but not necessarily limited to, the following factors:
The equivalency of CHAP's standards for HIT as compared
with CMS' HIT conditions for certification.
CHAP's survey process to determine the following:
++ The composition of the survey team, surveyor qualifications, and
the ability of the organization to provide continuing surveyor
training.
++ The comparability of CHAP's to CMS standards and processes,
including survey frequency, and the ability to investigate and respond
appropriately to complaints against accredited facilities.
++ CHAP's processes and procedures for monitoring a HIT supplier
found out of compliance with CHAP's program requirements.
++ CHAP's capacity to report deficiencies to the surveyed supplier
and respond to the suppliers' plan of correction in a timely manner.
++ CHAP's capacity to provide CMS with electronic data and reports
necessary for effective assessment and interpretation of the
organization's survey process.
++ The adequacy of CHAP's staff and other resources, and its
financial viability.
++ CHAP's capacity to adequately fund required surveys.
++ CHAP's policies with respect to whether surveys are announced or
unannounced, to assure that surveys are unannounced.
++ CHAP's agreement to provide CMS with a copy of the most current
accreditation survey together with any other information related to the
survey as CMS may require (including corrective action plans).
CHAP's agreement or policies for voluntary and involuntary
termination of suppliers.
CHAP agreement or policies for voluntary and involuntary
termination of the HIT AO program.
CHAP's policies and procedures to avoid conflicts of
interest, including the appearance of conflicts of interest, involving
individuals who conduct surveys or participate in accreditation
decisions.
IV. Collection of Information Requirements
This document does not impose information collection and
requirements; that is, reporting, recordkeeping or third party
disclosure requirements. Consequently, there is no need for review by
the Office of Management and Budget under the authority of the
Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq).
V. Response to Public Comments
Because of the large number of public comments we normally receive
on Federal Register documents, we are not able to acknowledge or
respond to them individually. We will consider all comments we receive
by the date and time specified in the DATES section of this preamble,
and, when we proceed with a subsequent document, we will respond to the
comments in the preamble to that document.
Upon completion of our evaluation, including evaluation of comments
received as a result of this notice, we will publish a final notice in
the Federal Register announcing the result of our evaluation.
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Seema Verma, having reviewed and approved this document,
authorizes Evell J. Barco Holland, who is the Federal Register Liaison,
to electronically sign this document for purposes of publication in the
Federal Register.
Dated: April 14, 2020.
Evell J. Barco Holland,
Federal Register Liaison, Department of Health and Human Services.
[FR Doc. 2020-08796 Filed 4-24-20; 8:45 am]
BILLING CODE 4120-01-P